Loading...
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to ma...
Na minha lista:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
BMC
2022-04-01
|
Serier: | BMC Cancer |
Online adgang: | https://doi.org/10.1186/s12885-022-09576-3 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|